ReviewFrontiers in immunology2026
Case Report: Mercury exposure and anti-LGI1/Caspr2 autoimmune encephalitis: a case series and literature review on the paradoxical worsening after chelation therapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic mercury exposure may be a potential risk factor for anti-LGI1/Caspr2 autoimmune encephalitis (AE). The effect of chelation therapy on coexisting AE is unknown. Methods: We report three patients from West China Fourth Hospital, Sichuan University (September-November 2025) with confirmed chronic mercury exposure, anti-LGI1/Caspr2 antibody positivity, and DMPS chelation. Clinical course, antibody titers, and treatment response were analyzed. Results: Within 1-3 days of chelation initiation, all three patients developed acute neuropsychiatric deterioration, a phenomenon not previously documented. Each patient fully recovered with prompt immunotherapy, with favorable long-term outcomes (mRS 0-2). This observation appears to contrast with experimental animal models where chelators attenuate rather than exacerbate autoimmune neuroinflammation. Conclusion: This series suggests that chelation therapy may be temporally associated with acute worsening in this specific population, highlighting a potential therapeutic dilemma: the standard treatment for mercury may, in some cases, be associated with exacerbation of the autoimmune process that may be related to its use. Screening for occult heavy metal exposure may be considered in unexplained AE, and immunotherapy should be initiated promptly if deterioration occurs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.